18F-Fluorocholine for the Detection of Parathyroid Adenomas

a study on Primary Hyperparathyroidism

Summary

Eligibility
for people ages 13 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
estimated completion
Principal Investigator
by Thomas Hope
Photo of Thomas Hope
Thomas Hope

Description

Summary

The investigators are studying the ability of F18 labeled fluorocholine PET to localize parathyroid adenomas in patients with hyperparathyroidism prior to surgery.

Keywords

Hyperparathyroidism, Primary Positron emission tomography Adenoma Parathyroid Neoplasms Hyperparathyroidism Fluorocholine PET

Eligibility

You can join if…

Open to people ages 13 years and up

  • Biochemically proven hyperparathyroidism and an indication for surgery
  • Age ≥ 13 years
  • Karnofsky performance status of > 50 (or ECOG/WHO equivalent).
  • Ability to understand a written informed consent document, and the willingness to sign it.

You CAN'T join if...

  • Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the PET scanner due to BMI.
  • Inability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.).
  • Inability to complete the needed investigational due to other reasons (severe claustrophobia, radiation phobia, etc.).
  • Pregnancy.

Location

  • UCSF Imaging Center at China Basin accepting new patients
    San Francisco California 94107 United States

Lead Scientist at UCSF

  • Thomas Hope
    Thomas Hope, MD, is the Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. He serves as Chief of Nuclear Medicine at the San Francisco VA Medical Center. He also serves as chair of the the Cancer Center’s Molecular Imaging & Radionuclide Therapy Site Committee.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT03764007
Phase
Phase 2/3
Study Type
Interventional
Last Updated
Contact us about this trial